Don't Ignore The Insider Selling In Maze Therapeutics
Some Maze Therapeutics, Inc. (NASDAQ:MAZE) shareholders may be a little concerned to see that the CEO & Director, Jason Coloma, recently sold a substantial US$594k worth of stock at a price of US$26.24 per share. However, it's crucial to note that they remain very much invested in the stock and that sale only reduced their holding by 7.8%.
The Last 12 Months Of Insider Transactions At Maze Therapeutics
In fact, the recent sale by Jason Coloma was the biggest sale of Maze Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at around the current price of US$26.21. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
Maze Therapeutics insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
View our latest analysis for Maze Therapeutics
I will like Maze Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 0.9% of Maze Therapeutics shares, worth about US$13m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
What Might The Insider Transactions At Maze Therapeutics Tell Us?
Insiders sold Maze Therapeutics shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. While insiders do own shares, they don't own a heap, and they have been selling. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Maze Therapeutics. Be aware that Maze Therapeutics is showing 4 warning signs in our investment analysis, and 1 of those is a bit unpleasant...
Of course Maze Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.